Drug Manufacturer Drug Wholesale Acquisition Cost Price Increase Reporting Instructions
Version (v): 07/13/2018; **Supersedes:** n/a
SB539 – Sec 4

Reporting Date:	On or before April 1; Exception July 1, 2018
Reporting Frequency:	Annually on or before April 1
Form Template Name:	"Drug Manufacturer WAC Reporting_template vmm.dd.yy"

Purpose: SB539 created the requirement for manufacturers of a prescription drug that appears on the most current list compiled by the Nevada Department of Health and Human Services according to Senate Bill 539, Sec. 3.6, Subsection 2, to report on the factors that contributed to the increase with an explanation of their role in the price increase; and any other information as prescribed.

Reporting Requirements Detailed in Senate Bill 539, Sec. 4, found at the following link:
https://www.leg.state.nv.us/App/NELIS/REL/79th2017/Bill/5822/Text

Instructions:

1. The department's excel template provides manufacturers with a standardized form to use for reporting that incorporates all the fields required by law in a classic format. Manufacturers may use alternate reporting formats if all the information required by law is supplied and clearly identified.
2. If using the department-provided template, all fields listed in the template document are required fields, unless otherwise noted.
3. If using the department-provided template, the departmental template headers should not be rearranged or changed in any way.
4. All values should be reported at the National level unless otherwise noted.
5. If prices increased for all formulations, dosages, and packaging variants of one drug due to identical factors, the drug manufacturer can submit one report per drug from the list compiled by the department according to SB539 section 3.6, subsection 2. Each NDC for which price increase factors are described should be listed in the report under the "NDC Code(s) (format XXXX-XXXX-XX)" field. If more than one NDC code is included in a cell, each NDC code should be separated by a semicolon.
6. For each drug reported, the manufacturer may report as many factors as required to justify the price increase. The total "% Influence of Factors" for each drug should equal 100%.
7. For technical assistance, send your questions to: drugtransparency@dhhs.nv.gov